SRRK Logo

Scholar Rock Holding Corporation (SRRK) 

NASDAQ
Market Cap
$2.69B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
728 of 776
Rank in Industry
400 of 433

Largest Insider Buys in Sector

SRRK Stock Price History Chart

SRRK Stock Performance

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as …

Insider Activity of Scholar Rock Holding Corporation

Over the last 12 months, insiders at Scholar Rock Holding Corporation have bought $0 and sold $46.9M worth of Scholar Rock Holding Corporation stock.

On average, over the past 5 years, insiders at Scholar Rock Holding Corporation have bought $23.78M and sold $13.6M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,189,781 shares for transaction amount of $15M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2023‑10‑16.

List of Insider Buy and Sell Transactions, Scholar Rock Holding Corporation

2024-10-08SaleCOO & CFO
37,187
0.1874%
$34.90$1.3M-3.26%
2024-10-07Saledirector
1.18M
4.967%
$29.25$34.39M-16.74%
2024-10-07SaleCOO & CFO
206,240
0.7912%
$26.56$5.48M-16.74%
2024-10-07SaleCHIEF MEDICAL OFFICER
109,375
0.4299%
$27.21$2.98M-16.74%
2024-10-07SaleCHIEF COMMERCIAL OFFICER
30,000
0.111%
$25.62$768,677-16.74%
2024-09-16SaleCHIEF SCIENTIFIC OFFICER
1,936
0.0026%
$8.58$16,611+241.60%
2024-08-16SaleCHRO
1,451
0.0018%
$9.33$13,538+0.75%
2024-06-17SaleGENERAL COUNSEL
4,695
0.0055%
$8.98$42,183+2.68%
2024-06-17SaleCOO & CFO
9,458
0.011%
$8.98$84,978+2.68%
2024-06-17SaleCHRO
4,305
0.005%
$8.98$38,680+2.68%
2024-06-17SaleCHIEF SCIENTIFIC OFFICER
2,315
0.0027%
$8.98$20,800+2.68%
2024-02-16SaleCHIEF EXECUTIVE OFFICER
11,614
0.016%
$15.74$182,842-15.88%
2024-02-16SaleCOO & CFO
4,744
0.0065%
$15.74$74,686-15.88%
2024-02-16SaleGENERAL COUNSEL
3,489
0.0048%
$15.74$54,928-15.88%
2024-02-16SaleCHRO
3,751
0.0052%
$15.74$59,053-15.88%
2024-02-16SaleCHIEF SCIENTIFIC OFFICER
2,512
0.0035%
$15.74$39,547-15.88%
2024-01-16SaleCOO & CFO
6,634
0.0092%
$15.93$105,670-11.38%
2024-01-16SaleGENERAL COUNSEL
4,186
0.0058%
$15.93$66,677-11.38%
2024-01-16SaleCHRO
2,849
0.004%
$15.93$45,381-11.38%
2024-01-16SaleSVP AND HEAD OF RESEARCH
2,002
0.0028%
$15.93$31,889-11.38%

Insider Historical Profitability

15.51%
AKKARAJU SRINIVASdirector
5612896
6.216%
$29.7411
Invus Public Equities, L.P.10 percent owner
11259438
12.4692%
$29.7441+13.03%
Invus Public Equities Advisors, LLCdirector
8850005
9.8009%
$29.7420
Samsara BioCapital GP, LLC10 percent owner
6788609
7.518%
$29.7410
SPRINGER TIMOTHY A
3273519
3.6252%
$29.7410+17.37%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Artal Group S A$199.97M14.1211.26M0%+$00.87
Fidelity Investments$188.3M13.2910.6M+1.8%+$3.34M0.01
T. Rowe Price$145.78M10.298.21M-1.36%-$2.01M0.02
Samsara Biocapital Llc$120.57M8.516.79M0%+$018.8
Redmile Group$114.01M8.056.42M+0.27%+$303,784.801.16
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.